EG435970 Inhibitors
EG435970 inhibitors represent a class of compounds designed to target and inhibit the activity of a specific molecular entity known as EG435970. These inhibitors are typically small molecules with a high degree of selectivity and potency for their target. The structural features of these inhibitors are tailored to achieve a specific binding affinity to EG435970, often by engaging key residues in its active site or allosteric sites. The binding of these inhibitors to EG435970 can disrupt its normal function, leading to a cascade of molecular changes in the cellular processes associated with this target. The structural diversity within this class of inhibitors allows for fine-tuning of their physical and chemical properties, such as solubility, stability, and cell permeability, which are crucial for their optimal interaction with EG435970 and their activity in various biological contexts.
The mechanism of inhibition for EG435970 inhibitors generally involves either competitive, non-competitive, or mixed-type inhibition, which is dictated by the compound's mode of binding. Competitive inhibitors compete directly with the natural substrate of EG435970, binding to its active site and preventing substrate processing. Non-competitive inhibitors bind to an alternate site, causing conformational changes that impede the normal activity of the target. This class of inhibitors may also exhibit varying degrees of selectivity based on their ability to distinguish between EG435970 and other structurally similar proteins. This selectivity is crucial for minimizing off-target effects and achieving desired specificity. In research settings, EG435970 inhibitors serve as valuable chemical tools to probe the function of EG435970 in various biochemical pathways, contributing to the understanding of its role in cellular signaling, regulation, and homeostasis. The development of these inhibitors often involves iterative structure-activity relationship (SAR) studies to enhance their efficacy and binding characteristics to EG435970.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Actinomycin D | 50-76-0 | sc-200906 sc-200906A sc-200906B sc-200906C sc-200906D | 5 mg 25 mg 100 mg 1 g 10 g | $74.00 $243.00 $731.00 $2572.00 $21848.00 | 53 | |
Actinomycin D directly inhibits Zfp936 by intercalating into DNA and preventing transcription. Its interference with the transcriptional machinery directly hinders the gene's predicted role in the regulation of gene expression within the nucleus. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $152.00 $479.00 $632.00 $1223.00 $2132.00 | 33 | |
Trichostatin A, a histone deacetylase inhibitor, indirectly inhibits Zfp936 by preventing histone deacetylation. This leads to an altered chromatin structure, indirectly influencing Zfp936's predicted involvement in the regulation of gene expression within the nucleus. | ||||||
Fluorouracil | 51-21-8 | sc-29060 sc-29060A | 1 g 5 g | $37.00 $152.00 | 11 | |
Fluorouracil directly inhibits Zfp936 by disrupting DNA synthesis. Its incorporation into RNA and DNA interferes with the gene's predicted role in regulating gene expression, impacting the nucleus's transcriptional activity. | ||||||
Curcumin | 458-37-7 | sc-200509 sc-200509A sc-200509B sc-200509C sc-200509D sc-200509F sc-200509E | 1 g 5 g 25 g 100 g 250 g 1 kg 2.5 kg | $37.00 $69.00 $109.00 $218.00 $239.00 $879.00 $1968.00 | 47 | |
Curcumin indirectly inhibits Zfp936 by modulating NF-κB signaling. Its impact on the NF-κB pathway influences Zfp936's predicted role in gene expression regulation within the nucleus, highlighting a potential indirect regulatory mechanism. | ||||||
A-485 | 1889279-16-6 | sc-507493 | 5 mg | $275.00 | ||
A-485, a PARP inhibitor, indirectly inhibits Zfp936 by affecting the poly(ADP-ribose) polymerase pathway. Its interference with PARP signaling indirectly influences Zfp936's predicted role in the regulation of gene expression, highlighting a potential indirect regulatory mechanism within the nucleus. | ||||||
(±)-JQ1 | 1268524-69-1 | sc-472932 sc-472932A | 5 mg 25 mg | $231.00 $863.00 | 1 | |
JQ1, a bromodomain inhibitor, indirectly inhibits Zfp936 by disrupting acetylated histone recognition. Its impact on bromodomain-containing proteins indirectly influences Zfp936's predicted role in the regulation of gene expression within the nucleus, suggesting an indirect epigenetic modulation. | ||||||
Etoposide (VP-16) | 33419-42-0 | sc-3512B sc-3512 sc-3512A | 10 mg 100 mg 500 mg | $51.00 $231.00 $523.00 | 63 | |
Etoposide directly inhibits Zfp936 by inducing DNA damage. Its impact on DNA topoisomerase II directly hinders the gene's predicted role in the regulation of gene expression within the nucleus, leading to transcriptional inhibition. | ||||||
Suberoylanilide Hydroxamic Acid | 149647-78-9 | sc-220139 sc-220139A | 100 mg 500 mg | $133.00 $275.00 | 37 | |
Suberoylanilide Hydroxamic Acid, a histone deacetylase inhibitor, indirectly inhibits Zfp936 by altering chromatin structure. Its impact on histone acetylation indirectly influences Zfp936's predicted role in the regulation of gene expression within the nucleus, suggesting an indirect epigenetic modulation. | ||||||
Camptothecin | 7689-03-4 | sc-200871 sc-200871A sc-200871B | 50 mg 250 mg 100 mg | $58.00 $186.00 $94.00 | 21 | |
Camptothecin directly inhibits Zfp936 by trapping DNA-topoisomerase I complexes. Its interference with topoisomerase I directly hinders the gene's predicted role in the regulation of gene expression within the nucleus, leading to transcriptional inhibition. | ||||||
BAY 11-7082 | 19542-67-7 | sc-200615B sc-200615 sc-200615A | 5 mg 10 mg 50 mg | $62.00 $85.00 $356.00 | 155 | |
BAY 11-7082 indirectly inhibits Zfp936 by targeting NF-κB signaling. Its impact on the NF-κB pathway influences Zfp936's predicted role in gene expression regulation within the nucleus, highlighting a potential indirect regulatory mechanism. | ||||||